Rocket Pharmaceuticals withdraws review application to FDA for RP-L102

Core Points - Rocket Pharmaceuticals has voluntarily withdrawn its biologics marketing application to the U.S. FDA for mozafancogene autotemcel (RP-L102), an investigational gene therapy for Fanconi Anemia [2] Company Summary - The withdrawal of the application follows a previously announced corporate decision by the company [2]